Company Profile
IceCure Medical Stock Price, News & Analysis
- Ticker:
- ICCM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
3.08 USD (-4.05%)
Close
Last updated: August 6, 2026
11.3M USD
Market cap
Why the stock is moving
Following the latest company update, “IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment”, ICCM closed down 4.05% at $3.08 on Aug 6, 2026. The move occurred in the trading session associated with this company update.
Company overview
Cryoablation Medical Technology
IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal.
ProSense
The ProSense system uses liquid nitrogen-based probes to create a controlled ice ball around a tumor under image guidance.
Breast Cancer Commercialization
FDA clearance supports use in selected early-stage breast cancer patients, providing the foundation for expanded U.S. installations and disposable probe utilization.
Broader Tumor Applications
The platform is also used or studied in kidney, liver, lung, and other tumors accessible to percutaneous cryoablation.
Future catalysts
The cleaner way to frame IceCure Medical right now is around its latest development priorities. The most useful line from the latest update is and North America May 12, 2026 8:30 am EDT Download as PDF Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as.... That should keep the program at the center of the company narrative for now.
Recent news
- 01
- 02
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
Source: IceCure Medical
- 03
- 04
- 05
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
Source: IceCure Medical
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of IceCure Medical (ICCM)?
IceCure Medical (ICCM) most recently closed at 3.08 USD, a -4.05% move versus the previous session.
What is the market cap of IceCure Medical (ICCM)?
IceCure Medical currently has a market capitalization of 11.3M USD on BioPharmSignal.
What does IceCure Medical do?
Cryoablation Medical Technology IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal. ProSense The ProSense system uses liquid nitrogen-based probes to create a controlled ice ball around a tumor under image guidance. Breast Cancer Commercialization FDA clearance supports use in...
On which exchange is ICCM stock listed?
IceCure Medical (ICCM) is associated with NASDAQ, Israel, Biopharma.
What is Cryoablation?
Cryoablation Medical Technology IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal.
Which conditions is IceCure Medical targeting with Cryoablation?
IceCure Medical is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does IceCure Medical describe recent progress with Cryoablation?
The cleaner way to frame IceCure Medical right now is around its latest development priorities. The most useful line from the latest update is and North America May 12, 2026 8:30 am EDT Download as PDF Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as.... That should keep the program at...
What is Medical?
Cryoablation Medical Technology IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal.